Study M1110

Study name	Zhou CH 2023a
Title	Effects of (S)-ketamine on depression-like behaviors in a chronic variable stress model: a role of brain lipidome
Overall design	The aim of this study was to clarify the changes in lipid composition in the hippocampus and prefrontal cortex in mice treated with a single i.p. injection of (S)-ketamine after 3 weeks of chronic variable stress (CVS) exposure. C57BL/6 mice were divided into the following 3 groups: (1) control group (non-stress with saline treatment, n =10), (2) CVS group (stress with saline treatment, n =10), and (3) CVS + ketamine group (stress with ketamine treatment at a single dose of 10 mg/kg (S)-ketamine once; n =11). Changes in the lipid compositions of the hippocampus and prefrontal cortex were analyzed with a mass spectrometry-based lipidomic approach.
Study Type	Type1; Type2;
Data available	Unavailable
Organism	Mouse; C57BL/6 mouse;
Categories of depression	Animal model; Chronic mild stress model; Chronic mild stress model;
Criteria for depression	Forced swimming test, tail suspension test
Sample size	31
Tissue	Central; Brain; Hippocampus; Central; Brain; Prefrontal cortex;
Platform	MS-based; LC-MS: ultra-HPLC with Q Exactive plus mass spectrometer (Thermo Fisher Scientific, Waltham, USA);
PMID	36874216
DOI	10.3389/fncel.2023.1114914
Citation	Zhou C, Zhao X, Ma X, et al. Effects of (S)-ketamine on depression-like behaviors in a chronic variable stress model: a role of brain lipidome. Front Cell Neurosci. 2023 Feb 15;17:1114914.
Metabolite	PC(36:4); SM(d42:2); LysoPC(14:0); PC(18:0/20:2); LysoPC(24:0/0:0); LysoPI(18:1); MGMG(16:0); PG(22:4/20:4); PI(16:0/20:3); PI(16:0/20:4); PI(16:0e/20:4); PI(20:4/20:4); SM(d33:1); PI(16:0/18:1); CL(76:8); PC(34:1e); SM(d42:1); PI(16:0/22:6); AcCa(16:1); GM2(d34:5); CerG2GNAc1(d32:1); SM(d37:1); SM(d39:2); SM(d41:1); SM(d18:1/24:2); SM(d35:1); SM(d36:1); AcCa(20:4); SM(t34:1); AcCa(22:6); Cer(m18:1/18:2); Cer(d17:1/18:0); PE(16:0/20:4); PI(16:0/20:5); PI(18:1/22:6); PI(10:0/20:4); PI(20:1/20:4); PI(16:0/16:0); PI(18:1e/20:4); PE(9:0/10:1); PE(20:1p/22:4); PI(16:0/22:4); PI(18:2/20:4); PE(13:0/10:4); PE(9:0/12:4); LysoPC(16:2e); PE(11:0/10:1); PE(18:1e/20:4); Cer(m44:3); WE(6:0/16:3); PC(18:1/24:0); PC(31:0/11:4); SM(d36:2); PC(8:1e/11:3); PC(26:1/12:4); SM(d18:1/18:4); WE(15:0/16:3); GD3(d38:2); MGDG(34:5); WE(8:0/18:3); SQDG(31:2e); DG(18:1/22:0); GM1(d36:2); phSM(t38:2); SQMG(16:0); WE(2:0/20:2); MGDG(40:2e); SM(d36:6); DGDG(43:10e); MGDG(18:1/24:0); SM(d34:2); SQDG(17:0/17:0); CerP(m19:0/15:0); MGDG(18:1/24:1); AcCa(18:0); MGDG(16:0/24:1); PC(16:2e/22:1); CL(21:0/22:6/16:1/18:1); GM1(d38:5); MGDG(38:3e); CL(87:5); CL(74:7); AcCa(18:1); StE(33:6); MGDG(16:0/26:0); MGDG(36:1e); MGDG(16:0/20:0); AcCa(16:0); MGDG(34:1e); Ubiquinone 7; MGDG(16:0e/22:1); AcCa(14:0); CL(83:5); CL(78:7); MGDG(16:0e/24:1); CerG2GNAc1(d34:4); MGDG(16:0/22:0); CL(23:0/16:0/22:1/22:6); SM(d18:2/21:3); PC(20:2/20:3); PG(20:0/22:6); DG(18:1/24:0); MGDG(32:0e); PG(42:0); PC(14:0/20:4); MGDG(44:4); MGDG(42:4); CL(17:0/20:0/18:0/22:4); MGDG(36:0e); MGDG(34:0e); PG(41:1); DG(18:1/24:1); DG(24:1/20:4); WE(6:0/16:2); DGDG(31:7); GM3(d36:1); CL(18:2/20:4/22:6/18:1); CL(80:12); CL(74:1); SM(d14:0/24:1); GM1(d36:1); WE(38:2); MGDG(40:0e); ST(d42:2); MGDG(38:2e); ST(d18:1/24:0); PA(48:4); SM(d34:0); PC(6:0/12:4); ZyE(35:6); SM(d44:2); SM(d32:1); SM(d18:0/22:1); MG(32:0); SM(d18:1/23:0); PC(18:1/18:1); ChE(22:6); PC(25:0/11:1); PC(20:1/18:1); ZyE(21:5); ChE(30:0); PC(34:0e); SM(d38:0); ZyE(20:5); ChE(2:0); MG(34:0); SM(d18:1/23:3); ST(t18:0/18:0); SM(d34:1); PC(16:0/18:3); WE(44:4); CL(76:4); WE(2:0/23:3); PIP3(26:6); WE(2:0/24:3); PE(11:0/10:3); PE(10:0/11:4); PS(22:1e); PE(17:0); WE(2:0/25:3); LPG(22:3); DG(19:3e); PI(18:0/20:3); PE(18:2e/20:1);